Amber Bio, a biotechnology company pioneering multi-kilobase gene editing platforms to reach previously undruggable diseases, launched today with an oversubscribed $26 million seed financing round co-led by Playground Global and Andreessen Horowitz Bio + Health. Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC also participated in the round.

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. The company is developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way.